Paul Elliot Mann Sells 83,758 Shares of ASP Isotopes (NASDAQ:ASPI) Stock

ASP Isotopes Inc. (NASDAQ:ASPI) CEO Paul Mann sold 83,758 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $3.91, for a total value of $327,493.78. Following the sale, the chief executive officer directly owned 9,496,087 shares of the company’s stock, valued at $37,129,700.17. This represents a 0.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Paul Elliot Mann also recently made the following trade(s):

• On Friday, September 4th, Paul Mann sold 83,759 shares of ASP Isotopes stock. The shares were sold at an average price of $4.10, for a total value of $343,411.90.

ASP Isotopes Stock Performance

Shares of ASP Isotopes stock opened at $4.20 on Friday. The company has a quick ratio of 3.85, a current ratio of 3.87 and a debt-to-equity ratio of 0.76. The stock’s fifty day moving average is $4.37 and its two-hundred day moving average is $5.20. ASP Isotopes Inc. has a 52 week low of $3.51 and a 52 week high of $14.49. The company has a market capitalization of $643.90 million, a PE ratio of -3.18 and a beta of 3.59.

ASP Isotopes (NASDAQ:ASPI) last released its earnings results on Friday, August 14th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.11). ASP Isotopes had a negative return on equity of 64.99% and a negative net margin of 427.98%.The business had revenue of $5.12 million for the quarter, compared to the consensus estimate of $4.47 million.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of ASP Isotopes in a report on Wednesday, June 24th. Wall Street Zen upgraded shares of ASP Isotopes from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 22nd. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $13.00.

Institutional Investors Weigh In On ASP Isotopes

Institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in shares of ASP Isotopes in the 2nd quarter worth $57,331,000. Encompass Capital Advisors LLC purchased a new position in shares of ASP Isotopes during the first quarter valued at $30,551,000. Alyeska Investment Group L.P. increased its stake in shares of ASP Isotopes by 73.4% during the fourth quarter. Alyeska Investment Group L.P. now owns 4,895,546 shares of the company’s stock valued at $26,191,000 after buying an additional 2,072,851 shares during the period. Vanguard Group Inc. raised its holdings in shares of ASP Isotopes by 37.9% in the third quarter. Vanguard Group Inc. now owns 4,516,763 shares of the company’s stock valued at $43,451,000 after acquiring an additional 1,241,024 shares in the last quarter. Finally, Rovida Investment Management Ltd raised its holdings in shares of ASP Isotopes by 28.1% in the fourth quarter. Rovida Investment Management Ltd now owns 4,100,000 shares of the company’s stock valued at $21,894,000 after acquiring an additional 900,000 shares in the last quarter. 16.80% of the stock is owned by institutional investors.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.